Concepedia

Clay B. Siegall

CB

45

Publications

4.2K

Citations

29

H-Index

1988

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

National Cancer Institute

National Institutes of Health

Bristol-Myers Squibb (Germany)

Seagen (United States)

Clay B. Siegall is an author at Bristol-Myers Squibb (United States) specializing in medicine, immunology, and cell biology.

Top concepts

Publications per year

1988–2005

45

Publications

45

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

, , +8

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 907 citations

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Alan F. Wahl, Kerry Klussman, Jennifer Thompson et al. · PubMed · 2002 · 212 citations

, , +18

Functional Analysis of Domains II, Ib, and III of Pseudomonas exotoxin

Clay B. Siegall, Vijay K. Chaudhary, David Fitzgerald et al. · Journal of Biological Chemistry · 1989 · 190 citations · Full text

Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.

Clay B. Siegall, G Schwab, Richard P. Nordan et al. · PubMed · 1990 · 154 citations

, , +13

Rows per page

1–5 of 45